<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00822861</url>
  </required_header>
  <id_info>
    <org_study_id>TPI ASM8-206</org_study_id>
    <nct_id>NCT00822861</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Four Escalating Dose Regimens of TPI ASM8 in Patients With Allergic Asthma</brief_title>
  <official_title>A Single Center, Open Label, Stepwise, Dose Profiling Study to Evaluate the Efficacy and Safety of Four Dose Regimens of Inhaled TPI ASM8 in Patients With Allergic Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pharmaxis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pharmaxis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      During this proposed clinical trial, the investigators intend to evaluate the pharmacodynamic
      anti-inflammatory properties and safety of TPI ASM8, by investigating the effect on sputum
      eosinophils and the airway responses during an allergen challenge at different dose levels.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The early and late asthmatic response were both significantly attenuated by the highest dose
      of ASM8. The methacholine challenge and other parameters (ECP, mRNA knockdown on CCR3 and
      B-Chain of IL-3-Il-5 and GMCSF were attenuated by ASM8.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2009</start_date>
  <completion_date type="Actual">February 2010</completion_date>
  <primary_completion_date type="Actual">February 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sputum eosinophils (%) on Day 4 versus Screening for each dose level.</measure>
    <time_frame>7 and 24 hrs post-allergen challenge</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability.</measure>
    <time_frame>Throughout the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma and sputum pharmacokinetic profile at the two highest dose levels.</measure>
    <time_frame>Dose level 3 and 4</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Dose level No.1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TPI ASM8 1 mg BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose level No.2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TPI ASM8 2 mg BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose level No.3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TPI ASM8 4mg BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose level No.4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TPI ASM8 8 mg Die</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TPI ASM8</intervention_name>
    <description>4 mg/mL, 1 mg BID for 4 days</description>
    <arm_group_label>Dose level No.1</arm_group_label>
    <other_name>ASM8</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TPI ASM8</intervention_name>
    <description>4 mg/mL, 2 mg BID for 4 days</description>
    <arm_group_label>Dose level No.2</arm_group_label>
    <other_name>ASM8</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TPI ASM8</intervention_name>
    <description>4 mg/mL, 4 mg BID for 4 days</description>
    <arm_group_label>Dose level No.3</arm_group_label>
    <other_name>ASM8</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TPI ASM8</intervention_name>
    <description>4 mg/mL, 8 mg OD for 4 days</description>
    <arm_group_label>Dose level No.4</arm_group_label>
    <other_name>ASM8</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women 18 to 65 years of age

          -  Generally good health; steroid naïve (or who have not taken inhaled/oral
             corticosteroid within last month) mild to moderate, stable, allergic asthma as defined
             by ATS criteria

          -  History of episodic wheeze and shortness of breath

          -  Forced expiratory volume in one second (FEV1) at baseline ≥ 70% of the predicted value

          -  Able to comprehend and follow all required study procedures; willing and able to sign
             an informed consent form.

        Exclusion Criteria:

          -  Significant acute or chronic medical or psychiatric illness

          -  Known coagulopathy, worsening of asthma or respiratory infection in the preceding 6
             weeks

          -  Use of inhaled or oral corticosteroids within the last 30 days, or need for
             antihistamines within 72 hours of each allergen or methacholine challenge,
             immunosuppressives, nonsteroidal anti-inflammatory drugs, or anticoagulants
             (intermittent doses of short-acting β2-agonist are allowed).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rene Pageau, B.Pharm M.Sc</last_name>
    <role>Study Director</role>
    <affiliation>Topigen Pharmaceuticals Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>McMaster University</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 3Z5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 13, 2009</study_first_submitted>
  <study_first_submitted_qc>January 14, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 15, 2009</study_first_posted>
  <last_update_submitted>November 14, 2013</last_update_submitted>
  <last_update_submitted_qc>November 14, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 15, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

